Redeye briefly comments on yesterday’s announcement that OncoZenge has resolved on two directed share issues, one to Vator Securities as compensation for its guarantee commitment in the recent rights issue, and one to settle the previous SEK2.0m bridge loan through set-off. The issues add approximately 1.45m shares, corresponding to dilution of about 5.5%, but preserve close to SEK4m in cash that would otherwise have been paid out.
LÄS MER
